New approaches to rapidly control foot-and-mouth disease outbreaks

References

• Murphy FA. Gibbs EP, Hotzinek MC, Studdert MJ. Wterintuy Virology. (3rd Edition) Academic Press, NY, USA (1999).
   Google Scholar
• Mason PW, Grubman MJ, Baxt B. Molecular basis of pathogenesis of FMDV. In: Foot-and-Mouth Disease. Rowlands D (Ed.). Virus es. 91, 9–32(2003).
   Google Scholar
• •Describes our current knowledge of the molecular biology of FMDV and the virus' interaction with its host.
   Google Scholar
• Leforban Y Prevention measures against foot-and-mouth disease in Europe in recent years. Vaccine 17, 1755–1759 (1999).
   PubMed Web of Science ®Google Scholar
• Brown E New approaches to vaccination against foot-and-mouth disease. Vaccine 10,1022–1026 (1992).
   PubMed Web of Science ®Google Scholar
• Doel TR FMD vaccines. In: Foot-and-Mouth Disease. Rowlands D (Ed.). Virus Res. 91, 81–99 (2003).
   PubMedGoogle Scholar
• •An informative review about the history of FMD vaccines and the current methods of vaccine production.
   Google Scholar
• Correa Melo E, Saraiva V, Astudillo V. Review of the status of foot and mouth disease in countries of South America and approaches to control and eradication. Rev. Sci. Tech. Off Int. Epiz 21, 429–436 (2002).
   PubMed Web of Science ®Google Scholar
• Yang PC, Chu RM, Chung WB, Sung HT Epidemiological characteristics and financial costs of the 1997 foot-and-mouth disease epidemic inTaiwan. Vet. Rec. 145, 731–734 (1999).
   PubMed Web of Science ®Google Scholar
• Knowles NJ, Samuel AR, Davies PR,Kitching RP, Donaldson AT. Outbreak of foot-and-mouth disease virus serotype 0 in the UK caused by a pandemic strain. Vet. Rec. 148, 258–259 (2001).
   PubMed Web of Science ®Google Scholar
• Chmitelin I, Moutou E Foot-and-mouthdisease: lessons to be learned from the experience of France. Rev. Sci. Tech. Off Int. Epiz. 21, 723–730 (2002).
   Web of Science ®Google Scholar
• Pluimers FH, Akkerman AM, Van der Wal P, Dekker A, Bianchi A. Lessons from the foot and mouth disease outbreak in the Netherlands in 2001. Rev. Sci. Tech. Off Int. Epiz 21, 711–721 (2002).
   PubMed Web of Science ®Google Scholar
• ••Explains the strategy The Netherlandsused to eradicate FMD in 2001, discusses the concerns of fanners and consumers with this strategy and as a result of these concerns proposes alternative control methods in the event of future outbreaks.
   Google Scholar
• Scudamore JM, Harris DM. Control of foot and mouth disease: lessons from the experience of the outbreak in Great Britain in 2001. Rev. Sci.Tech. Off Int. Epiz. 21, 699–710 (2002).
   PubMed Web of Science ®Google Scholar
• •An interesting overview of the 2001 FMD outbreak in the UK and the lessons learned from the governments prospective.
   Google Scholar
• Anon. Infectious disease in livestock The Royal Society (2002).
   Google Scholar
• ••This UK commissioned report is an in-depth analysis of the 2001 FMD outbreak by the Royal Society. homologous challenge after a single dose of replication-defective human adenovirus Type 5 expressing capsid proteins of foot-and-mouth disease virus (FMDV) strain A24. Vaccine 20, 1631-1639 (2002).
   Google Scholar
• Mayr GA, Chinsangaram J, Grubman MJ. Development of replication-defective adenovirus serotype 5 containing the capsid and 3C protease coding regions of foot-and-mouth disease virus as a vaccine candidate. Virology 263, 496–506 (1999).
   PubMed Web of Science ®Google Scholar
• Mayr GA, O'Donnell M, Chinsangaram J,Mason PW, Grubman MJ. Immune responses and protection against foot-and-mouth disease virus (FMDV) challenge in swine vaccinated with adenovirus-FMDV constructs. Vaccine 19, 2152–2162 (2001).
   PubMed Web of Science ®Google Scholar
• Moraes MP, Mayr GA, Mason PW, Grubman MJ. Early protection against
   Google Scholar
• Cedillo-Barron L, Foster-Cuevas M, Belsham GJ, Lefevre F, Parkhouse RM. Induction of a protective response in swine vaccinated with DNA encoding foot-and-mouth disease virus empty capsid proteins and the 3D RNA polymerase. J. Gen. Viral 82, 1713–1724 (2001).
   PubMed Web of Science ®Google Scholar
• Sanz-Parra A, Jimenez-Clavero MA, Garcia-Briones MM, Blanco E, Sobrino F, Ley V Recombinant viruses expressing the foot-and-mouth disease virus capsid precursor polypeptide (P1) induce cellular but not humoral antiviral immunity and partial protection in pigs. Virology 259, 129–134 (1999a).
   PubMed Web of Science ®Google Scholar
• Sanz-Parra A, Vazquez B, Sobrino F, Cox SJ, Ley V, Salt JS. Evidence of partial protection against foot-and-mouth disease in cattle immunized with a recombinant adenovirus vector expressing the precursor polypeptide (P1) of foot-and-mouth disease virus capsid proteins. J. Gen. Wrol 80, 671–679 (1999b).
   Google Scholar
• Wang CY, Chang TY, Walfield AM, et al Effective synthetic peptide vaccine for foot-and-mouth disease in swine. Vaccine 20, 2603–2610 (2002).
   PubMed Web of Science ®Google Scholar
• Wong HT, Cheng SC, Chan EW, et al Plasmids encoding foot-and-mouth disease virus VP1 epitopes elicited immune responses in mice and swine and protected swine against viral infection. Virology 278, 27–35 (2000).
   PubMed Web of Science ®Google Scholar
• Wong HT, Cheng SC, Sin FW, Chan EW, Sheng ZT, Xie Y. A DNA vaccine against foot-and-mouth disease elicits an immune response in swine which is enhanced by co-administration with interleukin-2. Vaccine 20, 2641–2647 (2002).
   PubMed Web of Science ®Google Scholar
• Graves JH, McKercher PD, Farris HE Jr, Cowan KM. Early response of catde and swine to inactivated foot-and-mouth disease vaccine. Res. Vet. Sci. 9, 35–40 (1968).
   PubMed Web of Science ®Google Scholar
• Sellers RF, Hemiman KAJ. Early protection of pigs against foot-and-mouth disease. Br. 14.t. J. 130, 440 445 (1974).
   Google Scholar
• Doel TR, Williams L, Barnett PV Emergency vaccination against foot-and-mouth disease: rate of development of immunity and its implications for the carrier state. Vaccine 12, 592–600 (1994).
   PubMed Web of Science ®Google Scholar
• Salt JS, Barnett PV, Dani P, Williams L Emergency vaccination of pigs against foot-and-mouth disease: protection against disease and reduction in contact transmission. Vaccine 16, 746–754 (1998).
   PubMed Web of Science ®Google Scholar
• Cox SJ, BarnettDani P, Sak JS.Emergency vaccination of sheep against foot-and-mouth disease: protection against disease and reduction in contact transmission. Vaccine 17, 1858–1868 (1999).
   PubMed Web of Science ®Google Scholar
• Biron CA, Sen GC. Interferons and other cytokines. In: Field's Virology. Knipe DM, Howley PM (Eds). Lippincott Williams Hc Wilkins, PA, USA, 321–351 (2001).
   Google Scholar
• Goodbourn S, Didcock L, Randall RE. Interferons: cell signalling, immune modulation, antiviral response and virus countermeasures. j Gen. Viral 81, 2341–2364 (2000).
   PubMed Web of Science ®Google Scholar
• Devaney MA, Vakharia VN, Lloyd RE, Ehrenfeld E, Grubman MJ. Leader protein of foot-and-mouth disease virus is required for cleavage of the p220 component of the cap binding protein complex. J. Viral 62, 4407–4409 (1988).
   PubMed Web of Science ®Google Scholar
• Chinsangaram J, Koster M, Grubman MJ. Inhibition of L-deleted foot-and-mouth disease virus replication by a/I3 interferon involves double-stranded RNA-dependent protein kinase. j Wrol 12, 5498–5503 (2001).
   Google Scholar
• Chinsangaram J, Piccone ME, Grubman MJ. Ability of foot-and-mouth disease virus to form plaques in cell culture is associated with suppression of a/I3 interferon./ Viral 73, 9891–9898 (1999).
   PubMed Web of Science ®Google Scholar
• Piccone ME, Rieder E, Mason PW,Grubman MJ. The foot-and-mouth disease virus leader proteinase gene is not required for viral replication. J. Wrol. 69, 5376–5382 (1995).
   Google Scholar
• Mason PW, Piccone ME, McKenna TS, Chinsangaram J, Grubman MJ. Evaluation of a live-attenuated foot-and-mouth disease virus as a vaccine candidate. Virology 227, 96–102 (1997).
   PubMed Web of Science ®Google Scholar
• Chinsangaram J, Mason PW, GrubmanMJ. Protection of swine by live and inactivated vaccines prepared from a leader proteinase-deficient serotype Al2 foot-and-mouth disease virus. Vaccine 16, 1516–1522 (1998).
   PubMed Web of Science ®Google Scholar
• Brown CC, Piccone ME, Mason PW, McKenna T St-C, Grubman MJ. Pathogenesis of wild type and leaderless foot-and-mouth disease virus in bovines. J. Viral 70, 5638–5641(1996).
   PubMed Web of Science ®Google Scholar
• Almeida MR, Rieder E, Chinsangaram J, et al Construction and evaluation of an attenuated vaccine for foot-and-mouth disease; difficulty adapting the leader proteinase-deleted strategy to the serotype 01 virus. Virus Res. 55, 49–60 (1998).
   PubMed Web of Science ®Google Scholar
• Chinsangaram J, Moines MP, Koster M, Grubman MJ. A novel viral disease control strategy: adenovirus expressing interferon a rapidly protects swine from foot-and-mouth disease./ Viral 77, 1621–1625 (2003).
   PubMed Web of Science ®Google Scholar
• ••Demonstrates, for the first time, thatpretreattnent with IFN-a successfully protects economically important animals against virus challenge.
   Google Scholar
• Proietti E, Bracci L, Puzelli S, et al Type I IFN as a natural adjuvant for a protective immune response: lessons from the influenza vaccine model. j Immun. 169, 375–383 (2002).
   PubMed Web of Science ®Google Scholar
• Babiuk LA, Ohmann HB, Gifford G,Can rniecki CW, Scialli VT, Hamilton EB. Effect of bovine al interferon on bovine herpesvirus Type 1-induced respiratory disease./ Gen. Viral 66, 2383–2394 (1985).
   PubMed Web of Science ®Google Scholar
• Brooks TJG, Phillpotts RJ. Interferon-alpha protects mice against lethal infection with St. Louis encephalitis virus delivered by the aerosol and subcutaneous routes. Antiviral Res. 41, 57–64 (1999).
   PubMed Web of Science ®Google Scholar
• Lukaszewski RA, Brooks TJG. Pegylated a interferon is an effective treatment for virulent Venezuelan equine encephalitis virus and has profound effects on the host immune response to infection. J. Viral 74, 5006–5015 (2000).
   PubMed Web of Science ®Google Scholar
• Noisakran S, Campbell IL, Carr DJJ. Ectopic expression of DNA encoding IFN-a 1 in the cornea protects mice from herpes simplex virus Type 1-induced encephalitis. Immund 162, 4184 4190 (1999).
   Web of Science ®Google Scholar
• Rosenquist BD, Allen GK Effect of bovine fibroblast interferon on rhinovirus infection in calves. Am. J. Vet. Res. 51, 870–873 (1990).
   PubMed Web of Science ®Google Scholar
• Schwers A, Severin JE, Bublot M, et al Protection of cattle from infection with vaccinia virus by bovine interferon aC. Vet. Rec. 125, 15–16 (1989).
   PubMed Web of Science ®Google Scholar
• Pawlotsky J-M. Mechanisms of antiviral treatment efficacy and failure in chronic hepatitis C. Antiviral Res. 59, 1–11(2003).
   PubMed Web of Science ®Google Scholar
• Heintges T, Petry W, Kaldewey M, et al. Combination therapy of active HbsAg vaccination and interferon-a in interferon-a nonresponders with chronic hepatitis B. Digest. Dis. Sd. 46,901–906 (2001).
   PubMed Web of Science ®Google Scholar
• Protzer U, Nassal M, Chiang P-W Kirschfink M, Schaller H. Interferon gene transfer by a hepatitis B virus vector efficiently suppresses wild type virus infection. Proc. NatlAcad. Sci. USA 96, 10818–10823 (1999).
   PubMed Web of Science ®Google Scholar
• Salmon P Le Cotonnec JY, Galazlca A,Abdul-Ahad A, Darragh A. Pharmacokinetics and pharmacodynamics of recombinant human interferon-I3 in healthy male volunteers./ Int. Cyt. Res. 16, 759–764 (1996).
   PubMed Web of Science ®Google Scholar
• Qin XQ, Tao N, Dergay Aet at Interferon-13 gene therapy inhibits tumor formation and causes regression of established tumors in immune-deficient mice. Proc. Natl Acad. Sci. USA 95,14411–14416 (1998).
   PubMed Web of Science ®Google Scholar
• Santodonato L, Ferrantini M, Palombo F, et al Antitumor activity of recombinant adenoviral vectors expressing murine IFN-a in mice injected with metastatic IFN-resistant tumor cells. Cancer Gene Ther. 8, 63–72 (2001).
   PubMed Web of Science ®Google Scholar
• Richmond JY, Hamilton LD. Foot-and-mouth disease virus inhibition induced in mice by synthetic double-stranded RNA (polyriboinosinic and polyribocytidylic acids). Proc. NatlAcad Sci. USA 64,81–86(1969).
   PubMed Web of Science ®Google Scholar
• Sellers RF, Hemiman KAJ, Leiper JWG,Planterose DN. The effect of double-stranded RNA of fungal origin on the development of foot-and-mouth disease in pigs and calves. Vet. Rec. 93,90–93 (1973).
   PubMed Web of Science ®Google Scholar
• McVicar JW, Richmond JY, Campbell CH,Hamilton LD. Observations of cattle, goats and pigs after administration of synthetic interferon inducers and subsequent exposure to foot and mouth disease virus. Can. J. Comp. Med. 37,362–368 (1973).
   PubMedGoogle Scholar
• Sellers RF, Hemiman KAJ. The effect of synthetic anionic polymer (pyran) on the development of foot-and-mouth disease in guinea-pigs, cattle and pigs. Res. Vet. Sci. 13,339–341 (1972).
   PubMed Web of Science ®Google Scholar
• Cunliffe HR, Richmond JY, Campbell CH.Interferon inducers and foot-and-mouth disease vaccines: influence of two synthetic polynudeotides on antibody response and immunity in guinea-pigs and swine. Can. J. Comp. Med 41,117–121(1977).
   PubMedGoogle Scholar
• Zhang J-F, Hu C, Geng Y, et al Treatment of a human breast cancer xenograft with an adenovirus vector containing an interferon gene results in rapid regression due to viral oncolysis and gene therapy. Proc. NatlAcad USA 93,4513–4518 (1996).
   PubMed Web of Science ®Google Scholar
• Aurisicchio L, Delmastro P Salucci V, et al Liver-specific a 2 interferon gene expression results in protection from induced hepatitis. J. Viral 74,4816–4823 (2000).
   PubMed Web of Science ®Google Scholar
• Karaca K, Sharma JM, Winslow BJ, et al Recombinant fowlpox viruses coexpressing chicken Type I IFN and Newcastle disease virus HN and F genes: influence of IFN on protective efficacy and humoral responses of chickens following in ovo or posthatch administration of recombinant viruses. Vaccine 16,1496–1503 (1998).
   PubMed Web of Science ®Google Scholar
• Torres JM, Alonso C, Ortega A. Mittal S, Graham F, Enjuanes L Tropism of human adenovirus Type 5-based vectors in swine and their ability to protect against transmissible gastroenteritis coronavirus. Viral 70,3770–3780 (1996).
   PubMed Web of Science ®Google Scholar
• Prevec L, Schneider M, Rosenthal KL,Belbeck LW, Derbyshire JB, Graham FL Use of human adenovirus-based vectors for antigen expression in animals. J. Gen. Viral 70,429–434 (1989).
   PubMed Web of Science ®Google Scholar
• Grubman MJ, Mason PW. Prospects, including time-frames, for improved foot-and-mouth disease vaccines. Rev. Sci. Tech. Off Int. Epiz 21,589–600 (2002).
   PubMed Web of Science ®Google Scholar
• Gogev S, Lemaire M, Thiry E. Prevalenceof antibodies to human adenovirus Type 5 in Belgian cattle. Vet. Rec. 148,752–754 (2001).
   PubMed Web of Science ®Google Scholar
• Moraes MP, Chinsangaram J, Brum MCS,Grubman MJ. Immediate protection of swine from foot-and-mouth disease: a combination of adenoviruses expressing interferon a and a foot-and-mouth disease virus subunit vaccine. Vaccine 22,268–279 (2003).
   PubMed Web of Science ®Google Scholar
• Wu Q, Brum MCS, Caron L, Koster M, Grubman MJ. Adenovirus-mediated Type I interferon expression delays and reduces disease signs in cattle challenged with foot-and-mouth disease virus./ Int. Cyt. Res. 23, 2371–2380 (2003).
   Web of Science ®Google Scholar
• Alexandersen S, Zhang Z, Donaldson Al, Garland AJM. The pathogenesis anddiagnosis of foot-and-mouth disease. J. Comp. Path. 129,1–36 (2003).
   PubMed Web of Science ®Google Scholar
• Zhang ZD, Hutching G, Kitching Alexandersen, S. The effects of y interferon on replication of foot-and-mouth disease virus in persistently infected bovine cells. Arch. Wrol. 147,2157–2167 (2002).
   Google Scholar
• Berger HG, Straub OC, Ahl R, Tesar M,Marquardt O. Identification of foot-and-mouth disease virus replication in vaccinated cattle by antibodies to non-structural virus proteins. Vaccine 8, 213–216 (1990).
   PubMed Web of Science ®Google Scholar
• Bergmann IE, de Mello PAE,Beck E, Gomes I, Neitzert. Diagnosis of persistent aphthovirus infection and its differentiation from vaccination response in cattle by use of enzyme-linked immunoelectrotransfer blot analysis with bioengineered nonstructural viral antigens. Am. J. Vet. Res. 54,825–831 (1993).
   PubMed Web of Science ®Google Scholar
• Hohlich BJ, Wiesmuller KH, Schlapp T,Haas B, Pfaff E, Saalmuller A.Identification of foot-and-mouth disease virus-specific linear B-cell epitopes to differentiate between infected and vaccinated cattle. j Viral 77, 8633–8639 (2003).
   Google Scholar
• Werling D, Jungi 1W TOLL-like receptors linking innate and adaptive immune response. Wt. Immunot Imm nopath. 91, 1–12 (2003).
   Google Scholar
• Pontarollo RA, Babiuk LA, Hecker R, vanDrunen Little-Van den Hurk S. Augmentation of cellular immune responses to bovine herpesvirus-1 glycoprotein D by vaccination with CpG enhanced plasmid vectors./ Gen. Wrol 83, 2973–2981 (2002).
   Google Scholar
• Baron S, Salazar A, Poast J. Protection by an interferon inducer in an animal model of smallpox: systemic protection does not predict dermal protection. 22nd Annual Meeting of the American Society for Virology Davis, CA, USA, W1-1,66 (2003).
   Google Scholar